SEARCH

SEARCH BY CITATION

References

  • 1
    Lavanchy D Hepatitis B virus epidemiology, disease burden, treatment, and current and merging prevention and control measures. Journal of Viral Hepatitis, 2004;11:97107.
  • 2
    Beasley RP Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer, 1988;61:19421956.
  • 3
    Bosch FX, Ribes J, Cleries R, Diaz M Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease, 2005;9:191211.
  • 4
    Izzedine H, Launay-Vacher V, Deray G Antiviral drug-induced nephrotoxicity. American Journal of Kidney Diseases, 2005;45:804817.
  • 5
    Brosgart C (1999) GS-417: a randomized, double-blind study of adefovir dipivoxil (ADV) at two dose levels (120 mg 60 mg) as part of combination therapy in NRTI-experienced patients with no prior PI therapy. Oral presentation, 12th International Conference on Antiviral Research; 1999 Mar 21–26.
  • 6
    Marcellin P, Chang T, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine, 2003;348:808816.
  • 7
    Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008;48:750758.
  • 8
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine, 2003;348:800807.
  • 9
    Hadziyannis S, Tassopoulos N, Heathcote EJ et al. Long-term (3-year) therapy with adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med, 2005;352:26732681.
  • 10
    Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology, 2003;38:14191427.
  • 11
    Peters MG, Hann H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 2004;126:91101.
  • 12
    Benhamou Y, Thibault V, Vig P et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. Journal of Hepatology, 2006;44:6267.
  • 13
    Ahmad M Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. Journal of Postgraduate Medicine, 2006;52:296297.
  • 14
    Izzedine H, Hulot JS, Launay-Vacher V et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney International, 2004;66:11531158.
  • 15
    Hostetler KY Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Research, 2009;82:A84A98.